NFP37 SOMATIC GENE THERAPY
ANNUAL MEETING
October 3,4,5, 2001

«Gene Therapy's plausible future»


last update 14.01.2002
Invited speakers

We thank all the speakers and specially the USA folks for braving
the arduous air-traffick situation
We also thank those who volunteered to fill in last-minute gaps,
thank to you all the meeting will be a success!

Name

status

Subject

*Michael Blaese
(Valigen Inc., Newtown, PA, USA)

confirmed

Therapy by Gene Repair
Genoplasty, DNA repair, monogenic diseases, DNA sequence conversion, MutS, Chimeraplast

*Olivier Danos
(Genethon, Paris, France)

confirmed

Biological and Clinical Features of AAV Vectors
Adeno-associated virus, viral vectors, immune response, skeletal muscle, neuromuscular diseases

*Leisa Johnson
(ONYX Pharmaceuticals Inc., Richmond, CA, USA )

confirmed

Oncolytic Viruses
Adenovirus, Cancer, Retinoblastoma, P53, E2F

*Alan Colman
(PPL therapeutics, Midlothian, UK)

confirmed

Potential of Animal Cloning Technologies in Future Therapies
nuclear transfer, reprogramming, imprinting, stem cells, cloning

*Katherine High
(Children's Hosp, Philadelphia, PA, USA)

confirmed

Gene-Assisted Treatment of Hemophilia. Adeno-associated vectors, blood clotting factor, clinical trial

*Holm Schneider
(Children's Hosp, Erlangen)

confirmed

In Utero Gene Therapy
aims, candidate diseases, choice of vectors, routes of administratiuon, animal models, developmental windows, ethical considerations

*Ian Graham (Univ London, Lodon UK)

confirmed

Oligonucleotide-based gene correction strategies: applications to neuromuscular and cardiovascular diseases
apolipoproteins, dystrophin, gene targeting, hyperlipidemia, muscular dystrophies, point mutation, antisense, RNA splicing

*Roland Mertelsmann (Uni Klinikum, Freiburg i. Br)

confirmed

Gene therapy and gene marking concepts in cancer treatment
gene marking, stem cells, cancer therapy, gene therapy

*Douglas Losordo (Tufts Univ, Boston, USA)

confirmed

Early results from clinical trials of gene therapy for myocardial angiogenesis.
Angiogenesis, VEGF, randomized clinical trial, endothelium, coronary arthery disease

back to page top
.

- GENERAL PROGRAM-


coffee breaks sponsored...

...by Invitrogen

back to page top
Wednesday, October 3

TIME

EVENT

Place/Speaker

0830-0900

coffee / registration

Hall Chemistry Building

0900

Welcome addresses

Director / President

0905-0955

Leisa Johnson
(ONYX Pharmaceuticals, Richmond, CA, USA )

Oncolytic Viruses
Adenovirus, Cancer, Retinoblastoma, P53, E2F

1000
1030

nfp37 poster ads/talks

1035

coffee break

1055
1130

nfp 37 poster ads /talks

1135

Olivier Danos
(Genethon, Paris, France)

Biological and Clinical Features of AAV Vectors
Adeno-associated virus, viral vectors, immune response, skeletal muscle, neuromuscular diseases

1210-1300

Poster session I, drinks, 1300 lunch


Hall , 'Salle de Lecture', Cafeteria EIF

1400
1525

short talks (nfp37 and /or guests)

1520

Coffee break

Hall

1600
1640

short talks (nfp37 and/or guests)

1645 -1730

Douglas Losordo
(Tufts, Boston, USA)

Early results from clinical trials of gene therapy for myocardial angiogenesis.
Angiogenesis, VEGF, randomized clinical trial, endothelium, coronary arthery disease

1800

Apero


back to page top
Thursday, October 4

coffee breaks sponsored...

...by Invitrogen

TIME

EVENT

Place/Speaker

0830-0900

coffee / registration

Hall Chemistry Building

0900

enter

Lecture Hall

0900-0945

Ian Graham
(Univ London, london, UK)

Oligonucleotide-based gene correction strategies: applications to neuromuscular and cardiovascular diseases
apolipoproteins, dystrophin, gene targeting, hyperlipidemia, muscular dystrophies, point mutation, antisense, RNA splicing

0950
1030

poster ads /talks

1035

coffee break

1055
1130

poster ads/talks

1135

Michael Blaese
(Valigen Inc., Newtown, PA, USA)

Therapy by Gene Repair
Genoplasty, DNA repair, monogenic diseases, DNA sequence conversion, MutS, Chimeraplast

1210-1300

Poster session II, drinks, 1300 lunch


Hall , 'Salle de Lecture', Cafeteria EIF

1400

1525

short talks

1520

Coffee break

Hall

1600
1640

short talks

1700 -1745

Katherine High
(Children's Hosp, Philadelphia, PA, USA)

Gene-Assisted Treatment of Hemophilia. Adeno-associated vectors, blood clotting factor, clinical trial

1800

Apero

1900

Official dinner


back to page top
Friday, October 5

coffee breaks sponsored...

...by Invitrogen

TIME

EVENT

Place/Speaker

0830-0900

coffee / registration

Hall Chemistry Building

0900

Welcome

Director

0910-0955

Roland Mertelsmann
(Univ Klinikum, Freiburg i. Br, Germany)

Gene therapy and gene marking concepts in cancer treatment
gene marking, stem cells, cancer therapy, gene therapy

1000
1030

Scientific presentations

Main Lecture Hall

1035

coffee break

1055
1230

Symposium 'Gene Therapy research in CH',
where to go?
R. Galeazzi
H. Diggelmann
F. Cavalli
K. Dorsch

1135

Press / media corner /residual presentations

Small Lecture Hall /large lecture Hall

1210-1330

lunch break / (posters?)


Hall , 'Salle de Lecture', Cafeteria EIF

1400

Presentation of the steering committee for a
Swiss Gene Therapy Network (SGTN)

Lecture Hall

1415

Holm Schneider
(Children's Hosp, Erlangen)

In Utero Gene Therapy
aims, candidate diseases, choice of vectors, routes of administratiuon, animal models, developmental windows, ethical considerations

1500

coffee break

1520

scientific presentations

main lecture hall

1640

Alan Colman
(PPL therapeutics, Midlothian, UK)

Potential of Animal Cloning Technologies in Future Therapies
nuclear transfer, reprogramming, imprinting, stem cells, cloning

1730

Meeting closure

hopefully:

see you at the next occasion proposed by SGTN


.
Technical SCHEDULE (updated 27.9, 1900)


WEDNESDAY 3.10

back to page top

Time

Name

Team

Abs Nr

min

Title

905

Johnson, L.

ONYX pharma., Richmond,USA

L01

45

Oncolytic Viruses

950

Hellwig, R.

HOSSLE

P02

5

Oligonucleotide-mediated Targeted Gene Repair Of X-linked Chronic Granulomatous ...

955

Bernasconi, L.

FONTANA

P03

5

Glioblastoma Multiforme Gene Therapy

1000

Dong, Z.

GUEST

P51

5

Overexpression Of Parkinson's Disease-associated Alpha-synuclein(a53t) In The ...

1005

Heister, T.

GUEST

P52

5

Hsv/aav Hybrid Vectors Mediate Long-term Gene Expression In Cultured Human Cells

1010

Hemmi, S.

GUEST

P53

5

Attenuated Replication-competent Adenoviruses As Tools For Melanoma Therapy

1015

Kostic, C.

GUEST

P54

5

Pattern Of Activity Of Viral And Housekeeping Gene Promoters Using Self-inactivating ...

1020

BREAK

COFFEE

1040

Pajusola, K.

GUEST

P55

5

Proteasome Activity And A Potentially Different Endosomal Routing Restrict Aav-2 ..

1045

Willers, J.

GUEST

P56

5

Interferon Resistance Of Cutaneous T-cell Lymphoma Derived Clonal T-helper 2 Cells ..

1050

Foletti, A.

RUEGG

M11

5

Disruption Of Integrin Function By Expressing Partial Regions Of The ...

1055

Iggo, R.

IGGO

M02

20

Adenoviruses With Tcf Binding Sites In Multiple Early Promoters Show Enhanced ...

1115

Villard, J.

VILLARD

M01

20

Diagnostic Test For Mhc Class Ii Deficiency Patients By Direct Genetic Correction

1135

Danos, O.

Genethon, Paris, France

L02

45

Biological And Clinical Features Of Aav Vectors

1220

BREAK

POSTERS & DRINKS

1230

Fuhrmann Benzakein, E.

HERRERA

P00

-

A Single-gene Approach To Devise Inducible Or Removable Therapeutic Genes: A General ...

1230

Genilloud, A.

RUSCONI

P01

-

Selection Of Spontaneously Translocating ...

1230

Matheux, F.

VILLARD

P04

-

Partial And Transient Restoration Of Mhc-ii Molecules In Rfx5-/- Mice By Lentiviral ...

1300

BREAK

POSTERS & LUNCH

1400

Aebischer, P.

AEBISCHER

M03

40

Lentiviral Vectors For The Treatment Of Neurodegenerative Disorders

1440

Wodnar-Filipowicz, A.

FILIPOWICZ/
Thali

M04

20

Lentivirus-mediated Gene Transfer Into Hematopoietic Precursor Cells From ...

1500

Rusconi, S.

FREY/Rusconi

M05

20

Selective Enhancement Of Gene Transfer By Steroid-mediated Gene Delivery (smgd).

1520

BREAK

REFRESHMENTS

1540

Greber, U.

GUEST

M51

20

Adenovirus-disassembly Reveals A Function Of Nuclear Histone-h1 In Viral Dna-import ..

1600

Hossle, J.

HOSSLE

M06

20

Progress In Somatic Gene Therapy Of X-linked Chronic Granulomatous Disease

1620

Baumgartner, I.

BAUMGARNTER

M07

20

Lessons Learned From Vegf Gene Therapy

1640

Losordo, D.

TUFTS, Boston, USA

L03

45

Early Results From Clinical Trials Of Gene Therapy For Myocardial Angiogenesis

1730

End-day1

REFRESHMENTS


THURSDAY 4.10

back to page top

Time

Name

Team

Abs Nr

min

Title

900

Graham, I.

Univ. London, Egham, UK

L04

45

Oligonucleotide-based Gene Correction Strategies: Applications To Neuromuscular And Cardiovascular Diseases

950

Arsenijevic, Y.

GUEST

P57

5

Lentiviral-mediated Transfer Of Ciliary ...

955

Lobianco, C.

AEBISCHER

P09

5

Dopaminergic Cell Loss Induced By Lentivir...

1000

Regulier, E.

AEBISCHER

P10

5

Lentiviral-mediated Delivery Of Mutant ...

1005

Odermatt, A.

FREY/Rusconi

P13

5

Selection Of Peptide Ligands Binding To The ..

1010

Ashrafuzzaman, M.

GUEST

P58

5

Harmonic Thermodynamical Behavior Of ...

1015

Esslinger, C.

GUEST

P59

5

Efficient Transduction Of Dendritic Cells And..

1020

Schafer, B.

GUEST

P60

5

Paired-box Containing Transcription Factor..

1025

Afanasieva, T.

KLEMENZ

P22

5

Single-chain Antibody And Its Derivatives ...

1030

BREAK

COFFEE

1050

Schultz, J.

MOELLING

P14

5

Ip-10 Encoding Plasmid Dna Immunization ...

1055

Schuemperli, D.

SCHUEMPERLI

M16

20

Stable Transduction And Expression Of ...

1115

Brun, C.

SCHUEMPERLI

P15

5

Exon Skipping Of Dystrophin Mrna By ...

1120

Jilek, S.

WALTER

P16

5?

Monitoring The Maturation Of Dendritic ...

1125

Kralisch, S.

WALTER

P17

5

Targeting Of Dendritc Cells By Specific...

1130

Li, J.

VASSALLI

P18

5

Adenoviral Gene Transfer Of A Soluble Il-1...

1135

Blaese, M.

VALIGEN Inc,
Newtown, USA

L05

45

Therapy By Gene Repair

1220

BREAK

POSTERS & LUNCH

1230

Bensadoun, J.

AEBISCHER

P06

-

Neuroprotective Effect Of Interleukin-6 And..

1230

Guillot, S.

AEBISCHER

P07

-

Long-term Gene Transfer To The Mouse ...

1230

Hussain-khan, H.

AEBISCHER

P08

-

Bioartificial Pancreas: Matching Device And ..

1230

Ridet, J.

AEBISCHER

P11

-

In Vivo Characterization Of A Tetracycline...

1230

Schneider, A.

SCHNEIDER/ Rusconi

P05

-

Exploring The Limits Of Organellar ...

1230

Schwenter, F.

AEBISCHER

P12

-

Optimization Of Human Erythropoietin ...

1230

Stolarczyk, D.

GUEST

P107

-

1300

BREAK

POSTERS & LUNCH

1400

Jones, G.

MERLO

M08

20

The Focal Adhesion Kinase (fak) Is Highly ...

1420

Kolakofsky, D.

KOLAKOFSKY

M09

20

Prolonging The Life Span Of Mature Dendritic.

1440

Scully, J.

REHMANN-SUT.

M10

20

Perceptions Of Healing Needs: Somatic Gene ...

1500

Moelling, K.

MOELLING

M12

20

Cytokine-encoding Dna For Cancer Gene...

1520

BREAK

REFRESHMENTS

1540

Walter, E.

WALTER

M13

20

Microparticle-mediated Transfection Of ...

1600

Bisoffi, M.

STADLER/ Cecchini

M14

20

Scavenger Receptor Block As Improved ...

1620

Mermod, N.

MERMOD

M15

20

A Regulatory Network For The Efficient ...

1640

High, K.

Children's Hosp., Phila.

L06

45

Gene-Assisted Treatment of Hemophilia

1730

End-day2

REFRESHMENTS

1900

Dinner

Invitees


FRIDAY 5.10:

back to page top

Time

Name

Team

Abs Nr

min

Title

900

Mertelsmann, R.

Uni-Klinikum,
Freiburg i.Br

L07

45

Gene Therapy And Gene Marking Concepts In Cancer Treatment

955

Kok, M.

DREHER

P20

5

Live Salmonella Vectors For Antigen Transfer Into Human Dendritic Cells.

1000

Obregon, C.

DREHER

P21

5

Salmonella Typhimurium Sipb Protein Modulates Activation And Release Of Il-18 ...

1005

Dreher, D.

DREHER

M17

20

From Genomics To Vaccination: Treatment Of Latent Tuberculosis By Recombinant ...

1025

BREAK

COFFEE

.

.

1045

Galeazzi, R.

INVITED PANELIST symp

none

30

NF and clinical research, report

1115

Diggelmann, H.

INVITED PANELIST symp

none

10

NF policy

1125

Cavalli, F.

INVITED PANELIST symp

none

10

The view of a Dr med/politician

1135

Dorsch, K.

INVITED PANELIST symp

none

10

Biosafety rules update

1145

All

EVENT/

panel and general discussion

1220

BREAK

POSTERS & LUNCH

1400

All

EVENT/

presentation of steering committee GT

1415

Schneider, H.

Children's Hosp. Erlangen, De

L08

45

In Utero Gene Therapy

1500

Seemayer, C.

GAY

M18

20

Gene Transfer For Treatment Of Rheumatoid Arthritis

1520

BREAK

REFRESHMENTS

1540

Wiznerowicz, M.

TRONO

M19

20

Hematopoietic Stem Cells-directed Gene Therapy: Chronic Granulomatous Disease

1600

Colman, A.

PPL Therapeutics Midlothian, UK

L09

45

Potential Of Animal Cloning Technologies In Future Therapies

1700

Closure

Safe return!

 


.

BRIEF GEOGRAPHIC DESCRIPTION (see below for maps):

page top

The annual meeting NFP37 will be hold at the Chemistry building
(this is number 9 in the plan of Perolles site).
We will post some signs: 'NFP37 ANNUAL MEETING'.

BY CAR:

BY TRAIN: at the train station entrance you can take a bus ticket (1.50 Fr).
Bus Nr 1 will bring you to Perolles (it is the terminal after a five stops ride, about 5 min).
If you want to walk, you take Blvd. de Perolles until its end (about 15 min).


.

FURTHER INDICATIONS AND MAPS:

page top


How to reach Fribourg (German): (http://www.unifr.ch/wwwunifr/body/planSuisseD.html)
How to reach Fribourg (French): (http://www.unifr.ch/wwwunifr/body/planSuisseF.html)

How to move around Fribourg (French): (http://www.unifr.ch/wwwunifr/body/planVilleF.html)
How to move around Perolles (French): (http://www.unifr.ch/wwwunifr/body/planPerollesF.html)

Railways Time table (english/french/german/italiano): (http://www.sbb.ch/)
Swissair Time Table (Zürich and Geneva) : (http://www.swissair.com/timetable/index.htm)

 

.

PARKING IN PEROLLES, legend to figure

page top

Parking will be free of charge during the meeting, please use area A

page top


.

LODGING DURING THE MEETING

page top

Speakers and other invitees will lodge at the:

NFP37 attendees who wish to arrive to Fribourg
the evening before, are recommended to reserve at
one of the following hotels (temporary list).
Please mention the word "Meeting Gene therapy/Gentherapie"
when you reserve a room in one of these hotels,
so you profit by a special price:

Hotels in the region:

(We are currently negotiating special rates for NFP37 attendees in these
and other hotels,including some bed-and-breakfast, so this list will become
longer in the next weeks)


.

Picture: Map of 'Central' Fribourg
grid-lines 0.5 km
back to text

Color

Lettering

Meaning

light purple dots

1-20

UNIFR sites, Perolles (Faculty of sciences) bears Nr 2

yellow dots

A-E

Hotels: A, Golden Tulip // B, Au Parc // C, Alpha // D, de la Rose // E, Sauvage // I, Elite // J, Cité St-Justin // K, Youth Hostel // L, Central

Red dot

F

Position of Institutes of Biochemistry and Chemistry

Blue dot

G

Position of the Ecole Ingenieurs (EIF)

Green dot

H

Train station

Green Dot

S

Restaurant San Marco (Dinner 4.10)


page top

Instructions for posters + 5 min ads


page top

Instructions for 20 min and 45 min oral communications


page top

Directions Train-station->Hotel Golden Tulip
(for invited speakers)


page top

Airports - Fribourg train schedules

Geneva Airport - Fribourg

 

Geneva Airport - Lausanne: 45 min
Lausanne-Fribourg: 45 min

-------------------------------------------------------------------------

Fribourg - Geneva Airport

-------------------------------------------------------------------------

Zurich Airport - Fribourg

 

Zurich Airport - ZH Hauptbahnhof: 10 min.
Zurich Airport - Bern: 90 min.
Zurich Hauptbahnhof - Bern: 70 min.
Bern-Fribourg 25 min
-------------------------------------------------------------------------

Fribourg - Zurich Airport

 

Fribourg - Bern: 20 min.
Fribourg - Zurich Hauptbahnhof: 95 min.

 

-------------------------------------------------------------------------

 


page top